HENDERSON, Nev.--(BUSINESS WIRE)--May 2, 2019--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host
a conference call with management to discuss the first quarter 2019
financial results, provide an update on the company's business, and
discuss expectations for the future on Thursday, May 9, 2019 at 4:30
p.m. Eastern/1:30 p.m. Pacific.
Thursday, May 9, 2019 @ 4:30 p.m. Eastern/1:30
(877) 837-3910, Conference ID# 4290388
(973) 796-5077, Conference ID# 4290388
For interested individuals unable to join the call, a replay will be
available from May 9, 2019 @ 7:30 p.m. ET/4:30 p.m. PT through May 16,
2019 until 11:59 p.m. ET/8:59 p.m. PT.
Domestic Replay Dial-In #:
(855) 859-2056, Conference ID# 4290388
International Replay Dial-In #:
(404) 537-3406, Conference ID# 4290388
This conference call will also be webcast. Listeners may access the
webcast, which will be available on the investor relations page
of Spectrum Pharmaceuticals' website: http://investor.sppirx.com/events-and-presentations
on May 9, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on
acquiring, developing, and commercializing novel and targeted drug
products, with a primary focus in hematology and oncology. Spectrum has
a strong track record of successfully executing across the
biopharmaceutical business model, from in-licensing and acquiring
differentiated drugs, clinically developing novel assets, successfully
gaining regulatory approvals and commercializing in a competitive
healthcare marketplace. Spectrum has a late-stage pipeline with novel
assets that serve areas of unmet need. This pipeline has the potential
to transform the company in the near future. More information on
Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations.These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future, including
certain company milestones, Spectrum's ability to identify, acquire,
develop and commercialize a broad and diverse pipeline of late-stage
clinical and commercial products, the timing and results of FDA
decisions, and any statements that relate to the intent, belief, plans
or expectations of Spectrum or its management, or that are not a
statement of historical fact.Risks that could cause actual
results to differ include the possibility that Spectrum’s existing and
new drug candidates may not prove safe or effective, the possibility
that our existing and new applications to the FDA and other regulatory
agencies may not receive approval in a timely manner or at all, the
possibility that our existing and new drug candidates, if approved, may
not be more effective, safer or more cost efficient than competing
drugs, the possibility that our efforts to acquire or in-license and
develop additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and quality
control and other risks that are described in further detail in the
company's reports filed with the Securities and Exchange Commission.The
company does not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in this
press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a
registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc.Any other
trademarks are the property of their respective owners.
© 2019 Spectrum Pharmaceuticals, Inc.All Rights Reserved
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005160/en/
Source: Spectrum Pharmaceuticals, Inc.
Vice President, Strategic
Planning & Investor Relations